Filing search / Lineage Cell Therapeutics, Inc. / "Nuclear"

8-K

EX-99.1

LCTX Lineage Cell Therapeutics, Inc.

9 Nov 23

Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

4:10pm

criteria on at least two non-adjacent B scans including: 1) reduction in outer plexiform layer (OPL) and/or inner nuclear layer (INL) subsidence; 2

8-K

LCTX Lineage Cell Therapeutics, Inc.

13 Dec 21

Regulation FD Disclosure

4:10pm

, external limiting membrane, and outer nuclear layer, which were not present at the time of baseline assessment. OpRegen is an allogeneic RPE cell … nuclear layer, which were not present at the time of baseline assessment. Reductions, or no progression for at least 1 year, was observed

8-K

EX-99.1

LCTX Lineage Cell Therapeutics, Inc.

13 Dec 21

Regulation FD Disclosure

4:10pm

ellipsoid zone, external limiting membrane, and outer nuclear layer, which were not present at the time of baseline assessment. These new and additive … limiting membrane, and outer nuclear layer, which were not present at the time of baseline assessment. Reductions, or no progression for at least 1

8-K

EX-99.1

m178nq wxst

1 Jun 21

Lineage Cell Therapeutics Reports Additional Cases of Retinal Tissue Restoration In Dry Amd Patients Treated with Opregen® Rpe Cells

7:00am

8-K

t7p0gv

1 Jun 21

Lineage Cell Therapeutics Reports Additional Cases of Retinal Tissue Restoration In Dry Amd Patients Treated with Opregen® Rpe Cells

7:00am

DEFA14A

uzw 6vzvnhw

7 Oct 13

Additional proxy soliciting materials

12:00am